

Direct effects of CPT-11 and SN38 on ovarian granulosa cells

TOMOKO UTSUNOMIYA^{1*}, TETSUJI TANAKA^{1*}, HIROTOSHI UTSUNOMIYA² and NAOHIKO UMESAKI¹

Departments of ¹Obstetrics and Gynecology, and ²Experimental Pathology, Wakayama Medical University, 811-1 Kimi-idera, Wakayama 641-0012, Japan

Received October 30, 2008; Accepted December 16, 2008

DOI: 10.3892/mmr_00000082

Abstract. This study aimed to clarify the mechanism by which apoptosis and Fas ligand (FasL) expression are induced in the ovarian granulosa cells of mice injected with irinotecan HCl (CPT-11). To this end, the direct effects of CPT-11 and its active metabolite, SN38, on granulosa cells were investigated. Normal ovarian tissue fragments obtained from 8-week-old female MCH mice were cultured *in vitro* with CPT-11 or SN38 and paraffin-embedded. After sectioning, the ovarian fragments were analyzed by TUNEL staining to detect apoptotic cells and by immunohistochemistry with an anti-FasL antibody to detect FasL expression. The results revealed no increase in TUNEL-positive granulosa cells in the ovarian tissue fragments cultured with CPT-11 or SN38. Furthermore, CPT-11 and SN38 did not induce FasL expression in the ovarian fragments. In conclusion, apoptosis and FasL expression induced in the ovarian granulosa cells of mice injected with CPT-11 is not caused by direct stimulation with CPT-11 or SN38. Therefore, systemic CPT-11 administration appears to induce apoptosis and FasL expression in granulosa cells via currently unknown endogenous FasL-inducing factors or by active metabolites of CPT-11 other than SN38.

Introduction

The anticancer drug irinotecan HCl (CPT-11) is converted into its main active metabolite, SN38, by carboxyl esterase in the body (1). SN38 is a powerful inhibitor of topoisomerase I and exhibits strong antitumor effects by antagonizing DNA synthesis (1). CPT-11 has been used clinically in various types of cancer chemotherapy, including that against uterine (2-4), ovarian (5-6), lung (7), colorectal (8-9) and gastric cancer (10),

as well as malignant lymphoma (11). High response rates to these therapies have been noted. Recently, we reported that pre- and perimenopausal cancer patients aged approximately 50 years and treated with CPT-11 combination chemotherapy frequently complained of menopausal malaise-like symptoms (MMLS), such as hot flashes, episodic sweating, peripheral chill, irritability and insomnia (12-13). In these patients, MMLS were completely relieved by estrogen therapy, indicating that they were induced by estrogen deficiency. In animal experiments using CPT-11-injected mice, Fas ligand (FasL) expression was specifically induced in the granulosa cells of ovarian large follicles and reacted with Fas antigens constitutively expressed on the granulosa cells, thereby inducing granulosa cell apoptosis (14). This is considered to represent one of the main mechanisms of CPT-11-induced ovarian failure in cancer patients. However, the mechanisms underlying the induction of apoptosis and FasL expression in the granulosa cells of CPT-11-injected mice remain unknown.

Regarding the development of novel preventive therapies for anticancer drug-induced ovarian failure, it is important to identify the factors that directly induce apoptosis and FasL expression in the granulosa cells of CPT-11-injected mice. Although an intraperitoneal injection of CPT-11 dose-dependently induces ovarian follicular apoptosis in mice (14), CPT-11 itself has very weak cytotoxic effects against cancer cells (1). Its metabolite, SN38, is considered to be the strongest antitumor molecule derived from CPT-11. Therefore, in the present study, we investigated the key factors involved in the direct induction of apoptosis and FasL expression in granulosa cells using organ culture experiments.

Materials and methods

Oophorectomy of mice after intraperitoneal injection of CPT-11. Animal experiments were carried out using 8-week-old female MCH mice (Nihon Clea Co. Ltd., Osaka, Japan). Each mouse received one intraperitoneal injection of CPT-11 (100 µg; Yakult Co., Ltd., Tokyo, Japan) in saline 48 h after an intraperitoneal injection of pregnant mare serum gonadotropin (5 units; Teikoku Zouki Co., Tokyo, Japan) to create similar ovarian conditions among the mice. Control mice received an intraperitoneal injection of saline rather than CPT-11. Under ether anesthesia, the abdomen was opened and the ovaries were dissected 24 h after CPT-11 administration. The isolated ovaries were fixed with 0.2% paraformaldehyde on ice overnight and embedded in paraffin.

Correspondence to: Dr Tetsuji Tanaka, Department of Obstetrics and Gynecology, Wakayama Medical University, 811-1 Kimi-idera, Wakayama 641-0012, Japan
E-mail: obgywmu@wakayama-med.ac.jp

*Contributed equally

Key words: apoptosis, granulosa cell, irinotecan, SN38, Fas ligand, ovarian failure, topoisomerase I inhibitor




Figure 1. TUNEL staining and immunohistochemical analysis of ovarian tissues after *in vitro* culture with CPT-11 or SN38. (A-D) TUNEL staining. (E-H) Immunohistochemistry for FasL expression. (A-C) and (E-G) *in vitro*-cultured ovarian fragments. (D and H) Ovaries excised from mice injected intraperitoneally with CPT-11. Almost no TUNEL-positive follicles were detected in the (B) CPT-11-treated or (C) SN38-treated ovarian tissues. No FasL-positive follicles are present in the (F) CPT-11-treated or (G) SN38-treated ovarian tissues. The ovaries from mice injected with CPT-11 contain (D) TUNEL-positive and (H) FasL-positive follicles.

In vitro organ culture of normal ovarian tissue fragments. Normal ovaries were removed from 8-week-old female MCH mice 48 h after an intraperitoneal injection of pregnant mare serum gonadotropin (5 units), cut into thin longitudinal fragments and cultured *in vitro* in 384-well culture plates (Genetix Ltd., New Milton, Hampshire, UK) in OPTI-MEM (Gibco-BRL, Gaithersburg, MD, USA) supplemented with 5% fetal calf serum (Equitech Bio Inc., Ingram, TX, USA), 100 U/ml penicillin (Gibco-BRL) and 100 µg/ml streptomycin (Gibco-BRL). CPT-11 or SN38 was added to the ovarian fragments and incubated for 5 h at 37°C in a 5% CO₂/5% O₂/90% N₂ atmosphere. The final concentrations of CPT-11 were 0, 0.2 and 2 µg/ml, while those of SN38 were 0, 2 and 20 ng/ml. For each experiment, six ovarian fragments from six ovaries were used. After the culture, these fragments were fixed with 0.2% paraformaldehyde in phosphate-buffered saline (PBS) overnight on ice and embedded in paraffin. Following sectioning, the paraffin-embedded tissues were analyzed by TdT-mediated dUTP-biotin nick end-labeling (TUNEL) staining to detect apoptotic cells, or were subjected to immunohistochemistry for FasL expression as described below. Ovarian follicles within the tissue sections obtained from the six ovaries were counted.

TUNEL staining of ovarian sections. Paraffin-embedded ovarian tissue sections were deparaffinized, treated with proteinase K (20 µg/ml; Roche Diagnostic, Mannheim, Germany) for 10 min at room temperature and washed four

times with distilled water for 5 min each at room temperature. Endogenous peroxidase activity in the sections was then blocked by incubation with 3% hydrogen peroxide in PBS for 5 min at room temperature. Finally, the sections were subjected to TUNEL staining using an ApopTag peroxidase *in situ* apoptosis detection kit (Serologicals Corporation, Billerica, MA, USA). TUNEL-positive follicles were defined as follicles containing at least 10 TUNEL-positive cells within an ovarian section. Experiments were performed twice to verify the results. The number of apoptotic and total follicles within the tissue sections obtained from six ovaries was counted, and the ratio of apoptotic to total follicles was calculated.

Immunohistochemistry for FasL expression. Paraffin-embedded tissue sections were deparaffinized and treated with 0.3% hydrogen peroxide in methanol to block endogenous peroxidase activity. Following antigen retrieval by microwave treatment at 100°C for 15 min in citrate buffer (1.8 mM C₆H₈O₇, 8.2 mM Na₃C₆H₅O₇, pH 6.0), the sections were incubated with anti-mouse FasL polyclonal rabbit IgG (1:1; Spring Bioscience, Fremont, CA, USA) at 4°C overnight, washed four times with PBS for 5 min each at room temperature, and incubated with a peroxidase-conjugated anti-rabbit secondary antibody (Simple Stain Max PO kit; Nichirei Co., Tokyo, Japan) for 30 min at room temperature. Finally, the sections were washed four times with PBS for 5 min each at room temperature, incubated with diaminobenzidine (Dako, Carpinteria, CA, USA) solution comprising of 30 mg




Figure 2. TUNEL-positive follicle ratios in ovarian tissues after *in vitro* culture with CPT-11 or SN38. Six ovarian fragments were cultured *in vitro* with CPT-11 or SN38 for 5 h. The number of total and TUNEL-positive follicles was counted, and the ratio of TUNEL-positive to total follicles calculated. In the six ovaries incubated with 2 ng/ml SN38 for 5 h, only one TUNEL-positive follicle was detected among 153 ovarian follicles examined (<1%).

diaminobenzidine in 150 ml of 0.05 M Tris-HCl (pH 7.6) containing 4% hydrogen peroxide and counterstained with methyl green (Nakalai Tesque Co. Ltd., Kyoto, Japan) at room temperature. FasL-positive follicles were defined as follicles containing at least 10 FasL-positive cells within an ovarian section. All experiments were performed twice to verify the results. The number of FasL-positive and total follicles within the tissue sections obtained from six ovaries was counted, and the ratio of apoptotic to total follicles was calculated.

Results

TUNEL-positive follicles in ovarian tissue fragments incubated with CPT-11 or SN38. Ovarian tissue fragments incubated with CPT-11 or SN38 were subjected to TUNEL staining to detect apoptotic cells. As shown in Fig. 1A-C, almost no TUNEL-positive follicles (containing ≥ 10 TUNEL-positive granulosa cells) were observed in either CPT-11- or SN38-treated ovarian fragments, whereas large follicles in the ovaries from the CPT-11-injected mice were TUNEL-positive (Fig. 1D). The number of TUNEL-positive follicles and total follicles in tissue sections obtained from six ovaries was counted, and the ratio of apoptotic follicles to total follicles was compared. As shown in Fig. 2, no TUNEL-positive follicles were detected in six non-treated ovaries and six CPT-11-treated ovaries after 5 h of culture. Only one TUNEL-positive follicle was detected among 70 follicles examined in six ovaries incubated with 20 ng/ml SN38. Similarly, only one TUNEL-positive follicle was observed among 153 follicles examined in six ovaries incubated with 2 ng/ml SN38.

FasL-positive follicles in ovarian tissue fragments incubated with CPT-11 or SN38. Ovarian tissue fragments incubated with CPT-11 or SN38 were evaluated for FasL expression by immunohistochemistry with an anti-FasL antibody. As shown in Fig. 1E-G, no FasL-positive follicles (containing ≥ 10 FasL-positive granulosa cells) were observed in either CPT-11- or SN38-treated ovarian fragments, whereas large and medium follicles in the ovaries from the intraperitoneally CPT-11-injected mice were FasL-positive (Fig. 1H).

Discussion

Ovarian failure caused by anticancer chemotherapy is usually irreversible, and cancer patients with post-chemotherapy ovarian failure often complain of estrogen deficiency symptoms or incurable sterility. However, the molecular mechanisms of anticancer drug-induced ovarian failure have yet to be clarified, and preventive therapies remain to be developed. A recent clinical endocrinological analysis revealed that CPT-11-combined chemotherapy often induces secondary amenorrhea and menopause in cancer patients (13). We previously demonstrated that one of the main mechanisms of CPT-11-induced ovarian failure is CPT-11-induced granulosa cell apoptosis in large ovarian follicles (14). Moreover, we showed that CPT-11-induced FasL expression in granulosa cells represents the main cause of CPT-11-induced granulosa cell apoptosis (14). These findings suggest that some ovarian failure induced by anticancer drugs may be prevented by inhibiting the induction of FasL expression in granulosa cells.

To develop preventive therapies for drug-induced ovarian failure, the key molecules inducing ovarian follicular injuries need to be identified. Therefore, in the present study, we examined whether CPT-11 or its metabolite SN38 directly induced granulosa cell apoptosis and/or FasL expression in granulosa cells. However, neither CPT-11 nor SN38 induced apoptosis or FasL expression in granulosa cells in our organ culture experiments. The incubation of ovarian tissues with CPT-11 and SN38 was carried out for 5 h in these organ cultures because overnight organ cultures produced spontaneous follicular destruction, and drug-induced ovarian apoptosis could not be evaluated. In rats intravenously injected with ^{14}C -CPT-11 (10 mg/kg body weight), the mean concentration of ^{14}C -CPT-11 derivatives in the ovaries 4 h after the injection was reported to be 1.9 $\mu\text{g/g}$ tissue weight (15-16). The ^{14}C -CPT-11 derivatives did not accumulate in either the testes or ovaries as compared with ^{14}C concentrations in the extragonadal organs. Intravenously injected CPT-11 is metabolized to its most active metabolite, SN38, within 30 min (17). Since most clinically administered CPT-11 disappears from the bloodstream within a few hours (17-18), the intraperitoneal injection of CPT-11 at 100 $\mu\text{g}/\text{mouse}$ (~ 18 -20 g body weight) represents a weaker stimulation than 5 h of direct exposure of ovarian fragments to high doses of CPT-11 or SN38. It is therefore highly unlikely that CPT-11 and SN38 are direct inducers of apoptosis and FasL expression in granulosa cells.

In a mouse *in vivo* study (14), CPT-11 increased apoptotic follicles in a dose-dependent manner. As neither CPT-11 nor SN38 is a direct inducer of apoptosis and FasL expression in granulosa cells, it is possible that CPT-11 stimulates tertiary factors in dose-dependent manners to induce apoptosis and FasL expression. Two possible hypotheses regarding such tertiary factors are proposed. First, unknown CPT-11-derived active metabolites other than SN38 (19) may directly induce apoptosis and/or FasL expression in granulosa cells. Second, unknown endogenous molecules stimulated by CPT-11 and/or SN38 may directly induce apoptosis and/or FasL expression in granulosa cells. However, the latter hypothesis is unlikely because no physiological ovary-specific apoptotic inducers have been identified to date. The identification of such factors is currently under investigation.

Acknowledgements

This study was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan.

References

1. Kawato Y, Aonuma M, Hirota Y, Kuga H and Sato K: Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. *Cancer Res* 51: 4187-4192, 1991.
2. Sugiyama T, Yakushiji M, Noda K, *et al*: Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer. *Oncology* 58: 31-37, 2000.
3. Umesaki N, Fujii T, Nishimura R, *et al*: Phase II study of irinotecan combined with mitomycin-C for advanced or recurrent squamous cell carcinoma of the uterine cervix: the JGOG study. *Gynecol Oncol* 95: 127-132, 2004.
4. Tanaka T, Kokawa K and Umesaki N: Preoperative chemotherapy with irinotecan and mitomycin for FIGO stage IIIB cervical squamous cell carcinoma: a pilot study. *Eur J Gynaec Oncol* 26: 605-607, 2005.
5. Tanaka T, Umesaki N and Ogita S: Camptothecin and mitomycin combination chemotherapy on ovarian clear cell carcinoma with multiple systemic metastases. *Eur J Gynaec Oncol* 11: 377-379, 2000.
6. Nishino K, Aoki Y, Amikura T, *et al*: Irinotecan hydrochloride (CPT-11) and mitomycin C as the first line chemotherapy for ovarian clear cell adenocarcinoma. *Gynecol Oncol* 97: 893-897, 2005.
7. Noda K, Nishiwaki Y, Kawahara M, *et al*: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. *N Eng J Med* 346: 85-91, 2002.
8. Saltz LB, Cox JV, Blanke C, *et al*: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. *N Eng J Med* 343: 905-914, 2000.
9. Douillard JY, Cunningham D, Roth AD, *et al*: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. *Lancet* 355: 1041-1047, 2000.
10. Yamao T, Shirao K, Matsumura Y, *et al*: Phase I-II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer. *Ann Oncol* 12: 1729-1735, 2001.
11. Tobinai K and Hotta T: Clinical trials for malignant lymphoma in Japan. *Jpn J Clin Oncol* 34: 369-378, 2004.
12. Tanaka T, Umesaki N and Ogita S: Effects of shakuyaku-kanzo-to on menopausal symptoms in an ovarian cancer patient treated with irinotecan HCl. *J Trad Med* 15: 456-457, 1998.
13. Tanaka T, Utsunomiya T, Utsunomiya H and Umesaki N: Irinotecan HCl, an anticancer topoisomerase I inhibitor, frequently induces ovarian failure in premenopausal and perimenopausal women. *Oncol Rep* 19: 1123-1133, 2008.
14. Utsunomiya T, Tanaka T, Utsunomiya H and Umesaki N: A novel molecular mechanism for anticancer drug-induced ovarian failure: Irinotecan HCl, an anticancer topoisomerase I inhibitor, induces specific FasL expression in granulosa cells of large ovarian follicles to enhance follicular apoptosis. *Int J Oncol* 32: 991-1000, 2008.
15. Hokusui H, Suzuki W, Atsumi R, *et al*: Studies on the metabolic fate of CPT-11 (1): pharmacokinetics in female rats following a single intravenous dose (1). *Xenobio Metab Dispos* 6: 73-95, 1991.
16. Atsumi R, Suzuki W, Hokusui H, *et al*: Studies on the metabolic fate of CPT-11 (4): pharmacokinetics in female rats following a single intravenous dose. *Xenobio Metab Dispos* 6: 137-149, 1991.
17. Kawato Y, Aonuma M, Matsumoto K and Sato K: Production of SN-38, a main metabolite of the camptothecin derivative CPT-11, and its species and tissue specificities. *Xenobio Metab Dispos* 6: 899-907, 1991.
18. Taguchi T, Wakui A, Hasegawa K, *et al*: Phase I clinical study of CPT-11. Research group of CPT-11. *Jpn J Cancer Chemother* 17: 115-120, 1990.
19. Slatter JG, Schaaf LJ, Sams JP, *et al*: Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. *Drug Metab Dispos* 28: 423-433, 2000.